Background:There have been few real-life dose-comparing studies on the efficacy and safety of secukinumab in Chinese patients with plaque psoriasis.We conducted a real-life cohort study to investigate the efficacy and...Background:There have been few real-life dose-comparing studies on the efficacy and safety of secukinumab in Chinese patients with plaque psoriasis.We conducted a real-life cohort study to investigate the efficacy and safety of secukinumab 150 and 300 mg in Chinese patients with moderate-to-severe plaque psoriasis.Methods:A total of 106 patients with moderate-to-severe plaque psoriasis were included in this study.Patients received either secukinumab 150 mg or secukinumab 300 mg according to patients’weights and severity of psoriasis.The treatment continued for at least 24 weeks.The efficacy was evaluated by improvement in the psoriasis area and severity index(PASI)scores.The safety was also analyzed.Results:Fifty-nine patients(55.7%)were treated with secukinumab 300 mg and 47 patients(44.3%)were treated with secukinumab 150 mg.After 12-week treatment,PASI75/90/100 responses were achieved in 100%,97.8%,and 95.7%of patients,respectively,in secukinumab 150 mg group,and the efficacy was maintained to week 24.In secukinumab 300 mg group,PASI75/90/100 responses were achieved in 93.2%,81.4%,and 76.3%of patients,respectively,at week 12.In this group,PASI75/90/100 responses reached 91.5%,86.4%,and 79.9%,respectively,at week 24.Biologic-experienced patients had lower responses than biologic-naïve patients.Secukinumab 150 and 300 mg were well tolerated.Five patients discontinued treatment due to poor response,adverse event,or economic reasons.Conclusions:This real-life study demonstrated that high PASI 90 and PASI 100 responses were achieved in Chinese psoriasis patients receiving secukinumab 150 or 300 mg.Biologic-naïve was associated with better clinical efficacy.展开更多
Thalidomide is an effective drug for the treatment of ankylosing spondylitis but might induce peripheral neuropathy. This major adverse reaction has attracted much concern. The current study aimed to observe the incid...Thalidomide is an effective drug for the treatment of ankylosing spondylitis but might induce peripheral neuropathy. This major adverse reaction has attracted much concern. The current study aimed to observe the incidence of thalidomide-induced peripheral neuropathy among an- kylosing spondylitis patients for 1 year after treatment. In this study, 207 ankylosing spondylitis cases received thalidomide treatment, while 116 ankylosing spondylitis cases received other treat- ments. Results showed that the incidence of thalidomide-induced peripheral neuropathy in the thalidomide group was higher than that in the non-thalidomide group. There was no significant difference in the incidence of neuropathy between the 〈 6 months medication and 〉 6 months medication groups. There were no differences in the mean age, gender, or daily dose between the two groups. The incidence of peripheral neuropathy among patients receiving 25, 50, 75, or 100 mg thalidomide per day was 4.6%, 8.5%, 17.1%, 21.7%, respectively. The incidence was significantly different between the groups receiving 25 mg and 100 mg thalidomide. In conclu- sion, thalidomide can induce peripheral neuropathy within 1 year after treatment of ankylosing spondylitis; however, age and gender have no obvious impact on the incidence of peripheral neuropathy. The incidence of peripheral neuropathy is associated with increasing daily doses of thalidomide.展开更多
文摘Background:There have been few real-life dose-comparing studies on the efficacy and safety of secukinumab in Chinese patients with plaque psoriasis.We conducted a real-life cohort study to investigate the efficacy and safety of secukinumab 150 and 300 mg in Chinese patients with moderate-to-severe plaque psoriasis.Methods:A total of 106 patients with moderate-to-severe plaque psoriasis were included in this study.Patients received either secukinumab 150 mg or secukinumab 300 mg according to patients’weights and severity of psoriasis.The treatment continued for at least 24 weeks.The efficacy was evaluated by improvement in the psoriasis area and severity index(PASI)scores.The safety was also analyzed.Results:Fifty-nine patients(55.7%)were treated with secukinumab 300 mg and 47 patients(44.3%)were treated with secukinumab 150 mg.After 12-week treatment,PASI75/90/100 responses were achieved in 100%,97.8%,and 95.7%of patients,respectively,in secukinumab 150 mg group,and the efficacy was maintained to week 24.In secukinumab 300 mg group,PASI75/90/100 responses were achieved in 93.2%,81.4%,and 76.3%of patients,respectively,at week 12.In this group,PASI75/90/100 responses reached 91.5%,86.4%,and 79.9%,respectively,at week 24.Biologic-experienced patients had lower responses than biologic-naïve patients.Secukinumab 150 and 300 mg were well tolerated.Five patients discontinued treatment due to poor response,adverse event,or economic reasons.Conclusions:This real-life study demonstrated that high PASI 90 and PASI 100 responses were achieved in Chinese psoriasis patients receiving secukinumab 150 or 300 mg.Biologic-naïve was associated with better clinical efficacy.
基金financially supported by the Natural Science Foundation of Liaoning Province of China,No.2014021081
文摘Thalidomide is an effective drug for the treatment of ankylosing spondylitis but might induce peripheral neuropathy. This major adverse reaction has attracted much concern. The current study aimed to observe the incidence of thalidomide-induced peripheral neuropathy among an- kylosing spondylitis patients for 1 year after treatment. In this study, 207 ankylosing spondylitis cases received thalidomide treatment, while 116 ankylosing spondylitis cases received other treat- ments. Results showed that the incidence of thalidomide-induced peripheral neuropathy in the thalidomide group was higher than that in the non-thalidomide group. There was no significant difference in the incidence of neuropathy between the 〈 6 months medication and 〉 6 months medication groups. There were no differences in the mean age, gender, or daily dose between the two groups. The incidence of peripheral neuropathy among patients receiving 25, 50, 75, or 100 mg thalidomide per day was 4.6%, 8.5%, 17.1%, 21.7%, respectively. The incidence was significantly different between the groups receiving 25 mg and 100 mg thalidomide. In conclu- sion, thalidomide can induce peripheral neuropathy within 1 year after treatment of ankylosing spondylitis; however, age and gender have no obvious impact on the incidence of peripheral neuropathy. The incidence of peripheral neuropathy is associated with increasing daily doses of thalidomide.
